Abstract

Hepatitis C virus (HCV) infection is a major public health burden in Europe, causing an increasing level of liver-related morbidity and mortality, characterized by several regional variations in the genotypes distribution.A comprehensive review of the literature from 2000 to 2015 was used to gather country-specific data on prevalence and genotype distribution of HCV infection in 33 European countries (about 80 % of the European population), grouped in three geographical areas (Western, Eastern and Central Europe), as defined by the Global Burden of Diseases project (GBD).The estimated prevalence of HCV in Europe is 1.7 % showing a decrease than previously reported (− 0.6 %) and accounting over 13 million of estimated cases. The lowest prevalence (0.9 %) is reported from Western Europe (except for some rural areas of Southern Italy and Greece) and the highest (3.1 %) from Central Europe, especially Romania and Russia. The average HCV viraemic rate is 72.4 %, with a population of almost 10 million of HCV RNA positive patients.Genotype distribution does not show high variability among the three macro-areas studied, ranging between 70.0 % (Central Europe), 68.1 % (Eastern Europe) and 55.1 % (Western Europe) for genotype 1, 29.0 % (Western Europe), 26.6 % (Eastern Europe) and 21.0 % (Central Europe) for genotype 3. Genotype 2 seems, instead, to have a major prevalence in the Western Europe (8.9 %), if compared to Eastern (4.3 %) or Central (3.2 %), whereas genotype 4 is present especially in Central and Western area (4.9 % and 5.8 %, respectively).Despite the eradication of transmission by blood products, HCV infection continues to be one of the leading blood-borne infections in Europe. The aim of this review is, therefore, to provide an update on the epidemiology of HCV infection across Europe, and to foster the discussion about eventual potential strategies to eradicate it.

Highlights

  • Hepatitis C virus (HCV) is one of the major globally prevalent pathogen and one of the main leading cause of death and morbidity in Europe [1,2,3]

  • Persistent HCV infection is generally associated with the development of liver cirrhosis, hepatocellular carcinoma (HCC), liver failure, and death [8], and a significant portion of liver transplantation in Europe is attributable to disorders related to Chronic Hepatitis C (CHC) [9]

  • Because epidemiological data are the basis for the development of preventive strategies able to eradicate HCV infection, the aim of this study is to systematically up-date and review HCV epidemiology throughout Europe to foster the development of country-specific screening programs and an international HCV surveillance program

Read more

Summary

Introduction

Hepatitis C virus (HCV) is one of the major globally prevalent pathogen and one of the main leading cause of death and morbidity in Europe [1,2,3]. About 3–4 million people are newly infected every year worldwide, and over 350,000 patients yearly die due to HCV-related disorders [4]. Persistent HCV infection is generally associated with the development of liver cirrhosis, hepatocellular carcinoma (HCC), liver failure, and death [8], and a significant portion of liver transplantation in Europe is attributable to disorders related to Chronic Hepatitis C (CHC) [9]. The limited effectiveness of treatments available until a couple of years ago have led HCV-associated mortality to exceed that due to the human immunodeficiency virus (HIV) in developed countries

Objectives
Methods
Findings
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call